Cancer antigen 125 (CA125) is the most used serum marker and the most trusted method for early detection of ovarian cancer. CD BioGlyco offers multiple highly sensitive and specific ovarian cancer assays based on CA125. We look forward to being your scientific assistant in the field of glycoproteomics.

CA125

Endometrial cancer, cervical cancer and ovarian cancer are three of the most common malignancies of the female reproductive tract. Of these three cancers, ovarian cancer, although rare, is the most lethal, primarily because approximately three-quarters of ovarian cancer cases are diagnosed at an advanced stage and the disease has spread to organs outside the ovaries. The poor prognosis for this cancer is directly attributable to the lack of sensitive and reliable screening assays and our limited understanding of its chemoresistance and recurrence mechanisms. Therefore, the establishment of appropriate early screening tests for ovarian cancer has long been sought.

One of the most commonly used protein tests for the initial detection of various types of cancer, including ovarian cancer, is based on serum levels of CA125 cancer antigen, which is a very important tumor glyco-biomarker with a normal level at 35 U/mL. This level is elevated in advanced ovarian cancer and in malignant tumors such as colon, breast, pericardium, pancreas and other epithelial cell diseases. Today, screening for ovarian cancer using CA125 is performed in combination with physical examination and its early detection is critical to achieving an effective ovarian cancer diagnosis so that treatment programs can be initiated at the onset of the disease.

Our Strategies

CD BioGlyco has developed sensitive, reliable and rapid methods for detecting low levels of CA125 that are indicative of early ovarian cancer. The strategies we provide include but are not limited to:

• We have developed an enzyme immunoassay based on a dual signal transduction mechanism for the detection of the glyco-biomarker CA125. The nanoelectrode array (NEA) is used to confirm the optical detection of CA125 in a highly bound 96-well plate. Alkaline phosphatase (AP) enzyme is used to label the detection antibody for optical and electrochemical detection of CA125.
• We have developed a label-free and array-based optical liquid-crystal immunoassay technique for the detection of CA125 antigen, providing an alternative and sensitive method for the detection of biomarker proteins.
• We have developed a dual gold nanostructure-based electrochemical immunosensor for the detection of the biomarker CA125 in serum. This immunosensor is stable and has good correlation coefficients for clinical serum samples tested using the developed immunosensor and enzyme-linked immunosorbent assay (ELISA).

Core Technologies

Our glyco-biomarker CA125 detection service is powered by a suite of cutting-edge technologies, ensuring unparalleled accuracy and sensitivity. A cornerstone of our approach is the use of particular lectin-based assays and advanced immunoassay techniques. We employ robust mass spectrometry platforms, including liquid chromatography-tandem mass spectrometry (LC-MS/MS), for the precise identification and quantification of glycosylation patterns associated with CA125. Furthermore, our service integrates high-throughput microfluidic systems, enabling efficient processing of numerous samples while maintaining exceptional data quality. These integrated technologies enable the detailed glycoprofiling of CA125, providing a deeper understanding beyond simple concentration measurements.

Unlocking Insights with CA125 Detection

• Our service scope encompasses the detection and analysis of CA125 in various biological matrices, including but not limited to serum, plasma, ascites fluid, ovarian cyst fluid, and tissue extracts.
• We offer both qualitative and quantitative analysis of CA125, focusing on its total concentration as well as its specific glycosylation patterns.
• Our capabilities extend to high-throughput screening for large cohorts, as well as in-depth characterization for specific research projects.

Workflow

Applications

• Biomarker Discovery and Validation: Our services can be used to identify and validate novel glyco-biomarkers related to CA125.
• Drug Development and Monitoring: Our services can be used to evaluate the effects of drugs on CA125 levels and their glycosylation patterns, providing insights into drug efficacy and mechanisms of action.
• Ovarian Cancer Research: Our services are based on research into the discovery, progression, and recurrence of ovarian cancer, and can be used for research into ovarian cancer markers at different stages.

Advantages of Us

• Our service utilizes cutting-edge glycomics and immunoassay technologies to achieve unparalleled sensitivity and specificity in CA125 detection, enabling the identification of subtle changes even at low concentrations.
• Beyond simple quantification, we provide detailed glycoprofiling of CA125. This allows for the identification of specific glycosylation patterns.
• Our stringent quality control measures and validated protocols ensure highly reproducible and reliable results, critical for consistent research outcomes.

Publication Data

Frequently Asked Questions

CD BioGlyco is committed to developing new cancer glyco-biomarker assays including CA125 assay to reduce the cost of detection systems and simplify cancer screening procedures. If you have a need for glyco-biomarker detection services, please contact us for further information.

Associated Services

To further support your research and development endeavors related to glyco-biomarkers and beyond, CD BioGlyco offers a range of complementary services:

• General Glycoprotein Glycoprofiling: If your research extends beyond CA125 to other glycoproteins, our comprehensive glycoprotein glycoprofiling service provides detailed analysis of N-linked and O-linked glycans on various target proteins.
  • N-Glycosylation Site Occupation

  • O-Glycosylation Site Occupation
• Biomarker Discovery and Validation Services: Leverage our expertise in identifying and validating novel biomarkers, integrating various omics data for a holistic view.
• Custom Synthesis: Access our capabilities in synthesizing specific glycan structures for use as standards or functional studies.